RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer
Status:
Recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
There is currently no standardized treatment for patients who have undergone first-line
standard treatment. In this study, We investigated the efficacy and safty of RC48 combined
with Tislelizumab in the second-line treatment of patients with HER2 expression in recurrent
cervical cancer.